GIMBHI: Alto Neuroscience (ANRO) Q3 2025 Earnings
Sources: Alto Neuroscience, Claude
Additional Information: Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Financial Performance
Cash $138M at Q3; $184M after PIPE
Runway projected into 2028
Net loss $14.2M (improved vs. $16.8M YoY)
R&D $10.5M (down from $13.1M YoY)
G&A $4.4M (down from $5.8M YoY)
No product revenue; typical clinical-stage cost structure
Accumulated deficit $185M (page 5 table)
Pipeline & Clinical Progress
ALTO-207 TRD program advancing rapidly post-FDA feedback
Phase 2b planned 1H 2026; Phase 3 targeted early 2027
Fixed-dose pramipexole + ondansetron design aims to improve tolerability and enable higher titration
ALTO-101 CIAS Phase 2 POC topline readout expected 1Q 2026
FDA Fast Track Designation awarded to ALTO-101
Theta ITC biomarker replicated and validated as robust EEG measure in schizophrenia datasets
ALTO-300 MDD Phase 2b topline expected mid-2026; targeting biomarker-positive patients
ALTO-100 bipolar depression Phase 2b topline expected 2H 2026
Blinded PK execution checks show high qualification (96–100%) across programs
Biomarker-selected patient cohorts used across multiple trials
Objective EEG + cognitive endpoints supplement traditional psychiatric scales
Business Model & Platform
Precision Psychiatry Platform integrating EEG, cognitive testing, and wearable data
Platform reused across TRD, MDD, BPD, and CIAS rather than drug-specific silos
Focus on matching neurobiological signatures to likely responders
Reuse of known molecules (pramipexole, agomelatine) with new biomarker logic
Transdermal PDE4 formulation (ALTO-101) designed to avoid tolerability issues of oral PDE4 inhibitors
Increasing operational rigor (PK verification, consistent enrollment timelines) embedded into platform identity
Development strategy emphasizes measurable, reproducible biological signals over broad diagnostic categories
Financing & Capital
$50M PIPE led by specialist biotech investors
Capital allocated to accelerate ALTO-207 development
Funding horizon covers four key readouts spanning 2026–2027
Raise sized to cross a dense catalyst window rather than extend runway indefinitely
Sector Themes & Observations
Psychiatry shifting toward quantifiable biomarkers (EEG, cognitive performance)
Trials increasingly pre-stratified to reduce patient heterogeneity
Combining digital neuro measures with known drugs reflects broader “precision-first” R&D in mental health
Multi-indication pipeline built from a shared measurement framework, not isolated programs
Design choices reflect an attempt to industrialize measurable psychiatry: reproducible biomarkers + operational precision + known mechanisms
The overall narrative resembles a move toward platformized neuropsychiatric drug development rather than single-asset biotech execution
Subscribe to news and reports about mental health startups & mental health investors at gimbhi.substack.com